Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process
Pacira BioSciences announced the successful transition of its PCRX-201 gene therapy to a scalable commercial manufacturing process, enabling the first patient enrollment in Part B of the Phase 2 ASCEND study. Part A enrollment has concluded with topline data expected by the end of 2026, while Part B will randomize approximately 90 patients to evaluate two dose levels of the therapy.
Key figures
- Phase
- Phase 2
- Dose a
- 1.4 × 10¹⁰ GC
- Dose b
- 1.4 × 10¹¹ GC
- Total patients
- approximately 135
- Part a patients
- 49
- Part b patients
- approximately 90
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.